Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Daiichi Sankyo
Harvard Business School
Boehringer Ingelheim
Colorcon
Dow
Merck
McKinsey
Farmers Insurance

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,168,218

« Back to Dashboard

Which drugs does patent 8,168,218 protect, and when does it expire?

Patent 8,168,218 protects RAYOS and is included in one NDA.

This patent has nineteen patent family members in eighteen countries.
Summary for Patent: 8,168,218
Title:Delayed release tablet with defined core geometry
Abstract: A press-coated tablet comprising a core containing an drug substance, and a coating, the core being disposed within the coating such that the coating has a first thickness about an axis A-B and a thickness about an orthogonal axis X-Y, such that the coating about the axis X-Y is thicker than the coating about the axis A-B, and is adapted to provide a lag time of between about 2 to 6 hours during which substantially no drug substance is released.
Inventor(s): Vergnault; Guy (Kembs Loechle, FR), Grenier; Pascal (Kappelen, FR), Dragan; Christophe (Geispitzen, FR)
Assignee: Jagotec AG (Muttenz, CH)
Application Number:10/554,538
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,168,218
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation; Device; Use;

Drugs Protected by US Patent 8,168,218

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-003 Jul 26, 2012 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY,GASTROINTESTINAL,DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,168,218

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0309342.4Apr 24, 2003
PCT Information
PCT FiledApril 23, 2004PCT Application Number:PCT/IB2004/001693
PCT Publication Date:November 04, 2004PCT Publication Number: WO2004/093843

Non-Orange Book US Patents Family Members for Patent 8,168,218

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,085 Delayed release tablet with defined core geometry ➤ Sign Up
8,309,124 Delayed release tablet with defined core geometry ➤ Sign Up
9,186,332 Delayed release tablet with defined core geometry ➤ Sign Up
8,394,407 Delayed release tablet with defined core geometry ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Covington
Accenture
Julphar
McKinsey
McKesson
Deloitte
Cantor Fitzgerald
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.